FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:2669-2671 June 18, 2009 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Vascular normalization, or restoration of the normal structure and function in blood vessels, has emerged as a strategy to treat cancer and other vascular disorders.¹ Mazzone et al.² have recently proposed a new approach for vascular normalization — targeting the prolyl hydroxylase domain 2 (PHD2) protein, an oxygen sensor that tags hypoxia-induced transcription factors for degradation. These authors found that haplodeficiency (i.e., half the "normal" dose) of PHD2 in endothelial cells "normalizes" abnormal endothelial cells in tumors, resulting in increased tumor oxygenation and decreased metastasis.²

In normal tissues, the balance between proangiogenic and antiangiogenic signaling maintains the normal structure of . . . [Full Text of this Article]

Source Information

From the Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School — both in Boston.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.